BLAINJECTIONINJECTABLE
Approved
Mar 2015
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
ZARXIO (filgrastim-sndz) by Novartis. Approved for leukocyte growth factor [epc]. First approved in 2015.
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZARXIO (filgrastim-sndz) is a recombinant human granulocyte colony-stimulating factor (G-CSF) administered by injection that stimulates the proliferation and differentiation of neutrophil precursor cells. It is indicated for chemotherapy-induced neutropenia and other conditions requiring leukocyte growth factor support. ZARXIO works as a cytokine that enhances immune cell production, helping patients maintain adequate white blood cell counts during cancer treatment and other myelosuppressive therapies.
$0.0BPart D
Mechanism of Action
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Novartis is hiring 1 role related to this product
Worked on ZARXIO at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.